Sitagliptin (Januvia)
DPP-4 inhibitor · DPP-4 class · oral smd · Merck
Top dose
100 mg
HbA1c reduction
-0.79%
at week 24 · efficacy
AE discontinuation
2.5%
Status
approved
Pivotal trial
- Trial
- Monotherapy (HbA1c)
- Indication
- type 2 diabetes
- Duration
- 24 weeks
- ClinicalTrials.gov
- NCT00094770
- Sponsor
- Merck
Notes
Januvia: the flagship and best-selling DPP-4 inhibitor. Weight-neutral, well-tolerated, modest HbA1c effect (~-0.8%). Cardiovascular-neutral (TECOS). Off-patent; the class is in structural decline as incretins take share.